Related Experiment Video
Updated: Aug 7, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Antibiotics for treatment of resistant gram-positive coccal infections
Hossam Al-Tatari1, Nahed Abdel-Haq, Pimpanada Chearskul
1Division of Infectious Diseases, Children's Hospital of Michigan; Carman and Ann Adams, Department of Pediatrics, Wayne State University School of Medicine, Detroit 48201, USA.
Abstract:
Vancomycin is considered the workhorse for the treatment of most drug-resistant gram-positive bacterial infections. However, concerns have been raised regarding the increasing rates of vancomycin-resistant enterococci and the clinical shortcomings of vancomycin in the treatment of invasive Staphylococcus aureus infections. Resources have been committed to the development of antimicrobial agents with activity against these organisms. This review will focus on the newer antibacterial agents that have been developed for the treatment of resistant gram-positive pathogens. Included in this review are the agents: quinupristin-dalfopristin, linezolid, daptomycin, telithromycin, and tigecycline.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Development of Antibiotic Resistance
Acute Pyelonephritis II: Diagnostic Studies and Management
Inhibitors of Bacterial DNA Synthesis
